Background: Angiotensin AT 1 receptors use G protein-independent signals to stimulate protein synthesis. Results: Arrestin-dependent activation of ERK1/2 and Akt signaling regulates mTOR-p70/85S6K and p90RSK, leading to increased protein translation in HEK293 and primary vascular smooth muscle. Conclusion: Arrestin-dependent ERK1/2 and Akt signaling cooperatively regulate cell growth. Significance: Arrestin pathway-selective AT 1 receptor agonists stimulate Akt-mTOR signaling and protein translation.
ribosomes to regulate protein translation. All three steps of protein synthesis require a unique set of translation factors: the eukaryotic initiation, termination, and release factors; eIFs, eEFs, and eRFs, respectively. The Akt and ERK pathways ultimately converge on these translation factors; both p70S6K and p90RSK phosphorylate eIF4B at Ser-422 (6) and eEF2 kinase at Ser-366 (7) .
GPCRs, like the angiotensin AT1 receptor, have been shown to regulate both ERK1/2 and Akt through non-canonical G protein-independent signaling mechanisms involving arrestins. Arrestin-dependent activation of ERK1/2 is one of the prototypic arrestin-mediated signals (8) . Ligand-dependent recruitment of arrestin to the receptor promotes assembly of a stable cRaf1-MEK-ERK1/2 signalsome complex, leading to activation of a discrete cytosolic pool of activated ERK1/2 (8, 9) . Signalsome-bound ERK1/2 cannot translocate to the nucleus and is transcriptionally silent (10, 11) , but has been reported to promote phosphorylation of cytosolic ERK1/2 substrates, including p90RSK and MNK-1, and to stimulate protein synthesis (12, 13) .
Arrestins also scaffold a protein phosphatase 2A (PP2A)/ Akt/glycogen synthase kinase 3␤ (GSK3␤) complex, and in the central nervous system, ␤arrestin2 has been shown to provide tonic restraint of GSK3␤ signaling in dopaminergic neurons (14 -16) . Arrestin-dependent activation of Akt in response to GPCR stimulation has also been reported in HEK293 and vascular smooth muscle cells (VSMCs) (17, 18) . In HEK293 cells, AT 1 receptor-mediated Akt activation results from ligand-induced phosphorylation of the PP2A inhibitor, I2PP2A, which transiently inhibits PP2A bound to the signalsome complex, permitting phosphorylation of Akt on the activating phosphoinositide-dependent protein kinase 1 (PDK1) site, Thr-308, to rise (18) .
Given the capacity of arrestins to regulate both the ERK1/2 and Akt pathways via GPCR-arrestin signalsomes, we hypothesized that they may function in the control of protein translation by integrating the activity of the two principal pathways controlling mTORC1 (Fig. 1B) . We find that both angiotensin II (AngII) and the arrestin pathway-selective AT 1 (7, 19) , stimulate mTORC1-dependent protein translation in HEK293 and primary vascular smooth muscle cells. The responses are arrestin-dependent, and require both ERK1/2 and Akt activity. Both Akt and ERK1/2 contribute to activation of the mTORC1-p70S6K axis, while ERK1/2 is the principal activator of the MAPKAPK, p90RSK. These data underscore the pivotal role of arrestins in G protein-independent AT 1 receptor signaling and identify novel properties of arrestin pathway-selective agonist ligands.
EXPERIMENTAL PROCEDURES
Materials-PD98059, rapamycin, and LY294002 were from Calbiochem/Millipore (Billerica, MA). OSU03012 was from Selleck Chemicals (Houston, TX). PP242 and angiotensin II were from Sigma-Aldrich. The SII peptide [Sar-Arg-Val-IleIle-His-Pro-Ile] was synthesized by the Cleveland Clinic protein core facility (Cleveland, OH). 10 mM stock SII solutions were prepared in a 10 mM acetic acid, 9 mg/ml NaCl, 0.1% BSA vehicle. The pCR3.1zeo expression plasmid encoding flag epitope-tagged rat ␤arrestin2 has been previously described (20) . Double-stranded siRNAs targeting ␤arrestin1/2 (18) and control scrambled siRNA were from Qiagen (Germantown, MD). Control and rat ␤arrestin1/2 shRNA Lentiviral vectors were from Santa Cruz Biotechnology, Inc. (Dallas, TX). Cell culture medium and cell culture additives were from Invitrogen (Grand Island, NY). GeneSilencer TM transfection reagent was from Genelantis (San Diego, CA). FuGENE 6 was from Roche Diagnostics (Indianapolis, IN). Rabbit polyclonal anti␤arrestin1/2 was a gift from Robert J. Lefkowitz (Duke University, Durham, NC). Anti-phospho-ERK1/2 IgG (Thr-202/Tyr-204; 9101), anti-ERK1/2 IgG (4695), anti-phospho-p90RSK1 IgG (Thr-359/Ser-363; 9344), anti-GAPDH IgG, anti-phosphoAkt IgG (Thr-308; 4056), anti-Akt IgG (9272), anti-phosphop70S6K IgG (Thr-421/Ser-424; 9204), and phospho-mTOR (Ser-2448; 2971) were from Cell Signaling Technology (Beverly, MA). The anti-phospho-p70S6K antibody also detects the homologous phosphorylation events on p85S6K. EZ view red M2 anti-flag affinity resin was from (Sigma-Aldrich). Horseradish peroxidase-conjugated donkey anti-rabbit and anti-mouse IgG were from Jackson Immuno-Research Laboratories, Inc. (West Grove, PA).
Cell Culture and Transfection-HEK293 cells stably expressing the rat AT 1A receptor (21) were maintained in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% fetal bovine serum, and 1% antibiotic/antimycotic solution. Prior to experimentation, cells were serum-deprived overnight in serum-free growth medium supplemented with 0.1% bovine serum albumin and 1% antibiotic/antimycotic solution. Transient transfection of HEK293 cells for flag-␤arrestin2 immunoprecipitation was performed in 10 cm dishes (8 million cells/ dish) using FuGENE 6 according to the manufacturer's instructions with 10 g of plasmid DNA per dish and 3 l of FuGENE 6 per g of DNA.
Primary rat aortic VSMCs were isolated and maintained as described previously (22) . VSMCs were cultured in minimum essential medium supplemented with 10% fetal bovine serum and 1% antibiotic/antimycotic solution. Cells were fed every 2 days and subcultured upon reaching 90% confluence. Prior to each experiment, cells were incubated for 24 to 48 h in serumfree growth medium supplemented with 0.1% bovine serum albumin and 1% antibiotic/antimycotic solution. All experiments employing primary VSMC were performed between passages four and nine.
Silencing ␤arrestin1/2 Expression by RNA Interference-The HEK293 FRT/TO ␤arrestin1/2 shRNA cell line carrying tetracycline-inducible shRNA simultaneously targeting the ␤arrestin1 and 2 isoforms (5Ј-CGTCCACGTCACCAACAAC-3Ј) was generated as previously described (20) . Transcription of shRNA was induced by 48 h exposure to 1 M doxycycline and down-regulation of ␤arrestin1/2 was documented by immunoblotting. Alternatively, transient down-regulation of ␤arrestin1/2 was performed using 19-nucleotide duplex siRNA with 3Ј dTdT overhangs. The sequence 5Ј-ACCUGCGCCUUCCGCUAUGTT-3Ј was used for silencing and the non-silencing RNA duplex 5Ј-AAUUCUCCG-AACGUGUCACGU-3Ј was used as the negative control. HEK293 cells at 50% confluence in 10 cm plates were transfected with 6 g of control or ␤arrestin1/2-targeted siRNA using 50 l of GeneSilencer TM according to the manufacturer's instructions. Assays were performed 72 h after gene silencing. Silencing of ␤arrestin1/2 expression was confirmed by immunoblotting.
For lentiviral down-regulation of ␤arrestin1/2 expression, VSMCs were grown to 70 -80% confluence then treated at a MOI of 50 with a 1:1 mixture of ␤arrestin1 and ␤arrestin2 shRNA lentiviral particles or cop GRP control lentiviral particles for 8 h in serum-free medium. Following infection, cells were incubated in complete medium for 24 h then incubated for 48 h in serum-free growth medium containing 0.1% BSA prior to treatment with 50 M SII for the times indicated. Silencing of ␤arrestin1/2 expression was confirmed by immunoblotting.
Protein Translation-The rate of net de novo protein synthesis was determined by L-[ 3 H]leucine pulse labeling. Subconfluent cells in 6-cm dishes were given a 2 h pulse of 5 Ci of L-[ were washed three times with ice-cold 0.5 N perchloric acid and resuspended in 0.3 N NaOH at 37°C for 1 h, after which 25 l of protein extract was added to 5 ml of scintillation mixture and 3 H dpm incorporated into protein determined by scintillation counting. Nonspecific counts measured in parallel plates that were lysed immediately following exposure to L-[ 3 H]leucine were background subtracted, and specific counts were normalized to total cellular protein determined by bicinchoninic acid protein assay (Pierce/Thermo Fisher Scientific).
Alternatively, protein translation rates were determined using the Click-iT AHA Alexa Fluor 488 Protein Synthesis High Content Screening Assay (Molecular Probes/Invitrogen, Grand Island, NY). Cells grown to subconfluence in 96-well plates were stimulated for 2 h as appropriate, and metabolically labeled for the last 30 min of incubation with the azide-containing amino acid, L-azidohomoalanine. Cells were then fixed and permeabilized, and labeled nascent protein was visualized using Click-iT chemistry that covalently attaches the fluorophore Alexa-488 to L-azidohomoalanine according to the manufacturer's protocol. Nuclei were counterstained using Hoechst 33342 dye. Cell monolayers were then imaged using an IN Cell High Content Analyzer (GE Healthcare Life Sciences, Pittsburgh, PA) to measure total levels of fluorescence in each field. Alexa-488 fluorescence was divided by the Hoechst 33342 fluorescence to normalize for cell number between fields.
Protein Immunoprecipitation and Immunoblotting-To assess the activation state of arrestin-bound Akt, HEK293-AT 1A cells were transiently transfected with pCR3.1zeo-flag␤arrestin2 and stimulated as described in the figure legends. Monolayers were lysed with 0.4 ml of ice-cold glycerol lysis buffer (50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; pH 7.5, 0.5% Nonidet P-40, 250 mM NaCl, 2 mM EDTA, and 10% glycerol) containing 10 mM N-ethyl-maleimide, 1 mM Na 3 VO 4 , 10 mM NaF, and protease inhibitor mixture. Lysates were clarified by centrifugation and flag-␤arrestin2 immunoprecipitated using 30 l of a 50% slurry of M2 anti-flag affinity resin with 2 h tumbling at 4°C. The resin was washed twice in lysis buffer, and proteins were eluted in Laemmli sample buffer for resolution by sodium dodecyl sulfate, polyacrylamide gel electrophoresis on 4 -20% gradient Tris-glycine gels (Invitrogen, Grand Island, NY). Immunoblots of phospho-ERK1/2, ERK1/2, phospho-Akt, Akt, phospho-p70/p85S6K, phosphop90RSK, ␤arrestin1/2, and GAPDH were performed using rabbit polyclonal IgG with HRP-conjugated goat anti-rabbit IgG as secondary antibody. Proteins were visualized using enhanced chemiluminescence (PerkinElmer, Wellesley, MA).
Because of its high molecular weight, samples for mTOR immunoblotting were resolved on 4 -12% Bis-Tris Gels (Invitrogen) run using 3-(N-morpholino)-propanesulfonic acid buffer and transferred to Invitrolon PVDF membranes using the wet-tank method. Membranes were blocked overnight in 5% milk in Tris-buffered saline-Tween 20 buffer. Primary antibodies were diluted 1:1000 in Tris-buffered saline-Tween 20 buffer and incubated overnight at 4°C. Membranes were washed five times and incubated with horseradish peroxidaseconjugated secondary antibody in Tris-buffered saline-Tween 20 buffer for 1 h at room temperature prior to development.
RESULTS
AT 1A Receptor-stimulated Protein Translation Requires ␤arrestin1/2, ERK1/2, and Akt Activity-The native AT 1 receptor ligand, AngII, initiates the full spectrum of AT 1 signaling, engaging both heterotrimeric G protein-and arrestin-regulated effectors. In contrast, the substituted octapeptide, SII (19) , is an arrestin pathway-selective AT 1 agonist with greatly diminished efficacy for heterotrimeric G protein activation, but near native ability to recruit arrestins and promote receptor internalization (9, 18, 19, 23) . Despite its lack of G protein efficacy, SII has been shown in global phosphoproteomic studies to elicit a robust protein phosphorylation response (18, 24, 25) .
To determine the role of arrestins, ERK1/2, and Akt in AT 1 receptor-stimulated protein translation, we employed both AngII and SII, since the former reflects physiological AT 1 activation, while the latter pharmacologically isolates the G protein-independent aspects of AT 1 signaling. As shown in Fig. 2 , the two ligands provoked similar increases in protein translation rate in HEK293-AT 1A cells measured either by L-[ Fig. 2B ) pulse labeling. AT 1 receptor-mediated stimulation of protein synthesis was blocked by the MEK1/2 inhibitor, PD98059, indicating that ERK1/2 is required for the response. Ligand-activated, but not basal, protein translation was also completely blocked by the PDK1 inhibitor, OSU03012. PDK1, which phosphorylates Akt on residue Thr-308, is the proximal kinase responsible for Akt activation.
To test whether the AngII or SII effects involved arrestins, we employed HEK293 FRT/TO ␤arrestin1/2 shRNA cells that were transiently transfected with the rat AT 1A receptor expression plasmid. Forty-eight h exposure of these cells to doxycycline results in 70 -90% down-regulation of ␤arrestin1/2 expression (Fig. 2B ). As shown, stimulation of protein translation by both AngII and SII was blocked by ␤arrestin1/2 silencing, suggesting that the AT 1A receptor predominantly uses arrestin-mediated pathways to couple to the translational machinery.
AT 1A Receptor Activation of Arrestin-bound Akt Is Independent of ERK Activation-Since the protein translation response to AngII and SII was co-dependent upon ERK1/2 and Akt activity, we next tested whether these two arrestin-regulated kinase cascades interacted proximally. As we previously described (18) , basal whole cell levels of Akt phosphorylation in HEK293 cells are constitutively high, necessitating that the phosphorylation state of the arrestin-bound Akt pool be measured in ␤arrestin2 immunoprecipitates. Fig. 3A shows the effects of PD98059 and OSU03012 on basal Akt phosphorylation in HEK293-AT 1A cells. As expected, no significant change in total cellular phospho-Akt was measurable in response to AngII or SII exposure (18) . Importantly, while the PDK1 inhibitor, OSU03012, dramatically reduced global Akt phosphorylation, the MEK1/2 inhibitor PD98059 had no effect, demonstrating that it did not nonspecifically affect Akt activity at the concentration employed. To determine the effect of agonist stimulation on the arrestin-bound pool of Akt, HEK293-AT 1A cells were transiently transfected with plasmid encoding flag␤arrestin2, and Akt phosphorylation was measured in flag-␤arrestin2 immunoprecipitates. As shown in Fig. 3B , both SII and AngII significantly increased the level of ␤arrestin2-bound phospho-Akt. The response was unaffected by ERK1/2 pathway inhibition, but was completely blocked by OSU03012, suggesting that arrestin-dependent activation of Akt is independent of concomitant ERK1/2 activation.
A degree of co-regulation was apparent in arrestin-dependent activation of ERK1/2. While AngII activates ERK1/2 via both Gq/11-protein kinase C and arrestin signaling, ERK1/2 activation by SII is exclusively arrestin-dependent and results from scaffolding of cRaf1-MEK-ERK1/2 in receptor-bound arrestin signalsomes (8, 9) . Thus, the possible involvement of PDK1-Akt in arrestin-dependent ERK1/2 activation could be determined from whole cell lysates of SII-stimulated cells. As shown in Fig. 3C , both AngII and SII increased whole cell ERK1/2 phosphorylation. Whereas SII was at least as effective as AngII at stimulating phosphorylation of the ␤arrestin2-bound Akt pool, the conventional ligand was more effective at activating ERK1/2 than the arrestin pathway-selective ligand. As expected, PD98059 inhibited ERK1/2 activation by both AngII and SII. SII-induced ERK1/2 phosphorylation was also partially sensitive to OSU03012 (SII ϩ vehicle ϭ 21.9 Ϯ 7.7-fold versus SII ϩ OSU03012 ϭ 8.4 Ϯ 4.0-fold; p ϭ 0.03; n ϭ 3), while the stronger AngII-mediated signal was not significantly affected. Similar results were obtained using the phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, as an alternative strategy to block Akt activation (Fig. 3D) . Consistent with prior reports (26) , this suggests PI3K-PDK1-Akt signaling may facilitate arrestin-dependent ERK1/2 activation.
Arrestin-dependent ERK1/2 and Akt Signaling Converges on p70S6K-Since arrestin-dependent activation of ERK1/2 and Akt appear to be largely independent at the signalsome level, yet both are required to stimulate protein translation, we next determined their contribution to regulation of the p70/85S6K and p90RSK pathways leading to translation initiation (Fig. 1A) .
The p70 and p85S6K isoforms are products of the same gene produced from alternative AUG translation start sites. Phosphorylation of p70S6K Thr-421/Ser-424, and the homologous sites on p85S6K, is required for activation, and both Akt and ERK1/2 reportedly regulate p70S6K (27) . As shown in Fig. 4A , treatment of HEK293-AT 1A cells with either PD98059 or OSU03012 completely blocked SII stimulated p70/85S6K phosphorylation. The SII effect was arrestin-dependent, since siRNA-mediated down-regulation of ␤arrestin1/2 also prevented the response (Fig. 4B) arrestin-bound Akt was not sensitive to PD98059 (Fig. 3B) , this suggests signals emanating from arrestin-ERK1/2 and arrestinAkt signalsome converge downstream at or before the level of p70/85S6K. AngII also induced phosphorylation of p70/ p85S6K. As with SII, the AngII response was blocked by PD98059 pretreatment; however it was only partially sensitive to OSU03012 (Fig. 4A ) and ␤arrestin1/2 silencing (Fig. 4B) , suggesting that alternative, probably G protein-mediated, pathways also contribute to the conventional agonist response.
The other arm of translational regulation is the ERK1/2-p90RSK cascade. ERK1/2 is known to activate p90RSK by direct phosphorylation of Thr-359/Ser-363. As shown in Fig. 4C , AngII-and SII-mediated p90RSK phosphorylation was inhibited by PD98059, consistent with previous reports that arrestindependent ERK1/2 signaling regulated the MAPKAPKs, p90RSK and MNK-1 (12, 13) . Neither AngII-nor SII-dependent p90RSK phosphorylation was significantly affected by OSU03012, although the PDK1 inhibitor appeared to blunt the SII response (SII ϩ vehicle ϭ 12.9 Ϯ 5.3-fold versus SII ϩ OSU03012 ϭ 7.1 Ϯ 0.9), perhaps reflecting the reduced efficiency of SII-stimulated ERK1/2 activation observed in the presence of OSU03012 (Fig. 3C) .
Arrestin-dependent ERK1/2 and Akt Signaling Regulates mTORC1 Activation and Function-Although arrestin-dependent ERK1/2 signaling appeared to be sufficient to activate p90RSK, SII-mediated activation of p70/85S6K required both ERK1/2 and Akt. Since mTORC1 is the critical upstream regulator of p70S6K, and is itself regulated by both ERK1/2 and Akt (Fig. 1A) , we next tested whether the two arrestin signaling pathways converged at the level of mTORC1.
The mTORC1 complex is regulated directly by Akt phosphorylation of mTOR Ser-2448 (28) , and indirectly by Akt and ERK1/2-p90RSK-mediated inhibition of TSC1/2 (1-3). As shown in Fig. 5A , both AngII and SII stimulated mTOR Ser-2448 phosphorylation. Both responses were abolished in the presence of OSU03012, which blocks ligand-dependent Akt activation (Fig. 3B) . mTOR Ser-2448 phosphorylation was also significantly reduced, but not blocked, by PD98059, Representative phospho-ERK1/2 and total ERK1/2 immunoblots are shown above a bar graph depicting the mean Ϯ S.E. of three biological replicates. In all panels; * greater than non-stimulated (NS), p Ͻ 0.05, n ϭ 3; † less than in the absence of inhibitor, p Ͻ 0.05, n ϭ 3.
consistent with the known modulatory role of ERK1/2-p90RSK. Since p70/85S6K is a direct mTOR substrate, we tested whether AT 1A receptor-mediated phosphorylation p70/85S6K was mTOR-dependent. As shown in Fig. 5B , SII-induced p70/ 85S6K phosphorylation was blocked by pretreatment with either rapamycin, an inhibitor of the raptor-containing mTORC1, or with PP242, a dual inhibitor of mTORC1 and the rictor-containing mTORC2, suggesting that the G protein-independent co-regulation of p70/85S6K by ERK1/2 and Akt occurs primarily at the level of mTOR. In contrast, AngII-mediated p70/85S6K phosphorylation was not significantly affected by rapamycin and while significantly reduced, was not abolished, by PP242, suggesting that the AngII response is less dependent on mTORC1 than the more arrestin-dependent SII response. This ability to bypass mTOR may reflect the enhanced efficacy of AngII for ERK1/2 activation (Fig. 3C) , since ERK1/2 can reportedly phosphorylate p70S6K directly (27) , and AngII-stimulated p70/85S6K phosphorylation is markedly inhibited by PD98059 in HEK293-AT 1A cells (Fig.  4A) .
We next tested whether AT 1A receptor-stimulated protein translation required mTORC1. As shown in Fig. 5C , treatment of HEK293 AT 1A cells with either rapamycin or PP242 completely inhibited SII-and AngII-stimulated of L-[ 3 H]leucine incorporation. Identical results were obtained using the L-azidohomoalanine incorporation method (Fig. 5D) .
AT 1 Receptor-mediated Protein Translation in Primary VSMCs Requires ERK1/2, Akt, mTORC1, and ␤arrestin1/2-As shown in Fig. 6A , both AngII and SII activate ERK1/2 in primary rat aortic VSMC (17) . Unlike HEK293 cells, primary aortic VSMC exhibit low basal levels of Akt phosphorylation, thus permitting detection of both AngII-and SII-induced Akt phosphorylation in whole cell lysates. As in HEK293 cells, SII-stimulated Akt phosphorylation was inhibited by down-regulating ␤arrestin1/2 expression (Fig. 6B) .
As shown in Fig. 6C , AngII-and SII-mediated Akt phosphorylation was detectable within 1 min of stimulation, peaked at 5 min, and returned nearly to baseline by 30 min. Ang II-stimulated ERK1/2 phosphorylation followed a similar time course, while SII-stimulated ERK1/2 phosphorylation was slightly delayed in onset, consistent with prior reports (29) . AngII stim- Representative phospho-p70/ 85S6K immunoblots are shown above a bar graph depicting the Mean Ϯ S.E. of three biological replicates. Glyceraldehyde phosphate dehydrogenase (GAPDH) was immunoblotted as a protein loading control. B, effect of ␤arrestin1/2 down-regulation on whole cell p70/85S6K phosphorylation. HEK293-AT 1A cells were transiently transfected with plasmid DNA encoding siRNA targeting ␤arrestin1/2 as described. Following serum-deprivation, cells were stimulated with AngII or SII for 5 min. Representative phospho-p70/ 85S6K and ␤arrestin1/2 immunoblots are shown above a bar graph depicting the mean Ϯ S.E. of three biological replicates. GAPDH was immunoblotted as a protein loading control. C, effect of ERK1/2 and Akt inhibitors on whole cell p90RSK phosphorylation. Serum-deprived HEK293-AT 1A cells were pretreated with PD98059 or OSU03012 prior to 5 min stimulation with AngII or SII. Representative phospho-p90RSK immunoblots are shown above a bar graph depicting the mean Ϯ S.E. of three biological replicates. GAPDH was immunoblotted as a protein loading control. In all panels; * greater than nonstimulated (NS), p Ͻ 0.05, n ϭ 3; † less than in the absence of inhibitor, p Ͻ 0.05, n ϭ 3. ulated ERK1/2 and Akt phosphorylation with similar potency (EC 50 ϳ0.4 nM; Fig. 6D ). Consistent with its known 200-fold lower affinity for the AT 1A receptor (19, 30) , SII was much less potent than AngII. In addition, the EC 50 of SII for ERK1/2 activation was about 5-fold higher than for Akt activation (ERK1/2 EC 50 ϭ 470 nM versus Akt EC 50 ϭ 85 nM), suggesting differences in the efficiency of coupling to the two pathways.
We next tested whether the SII-stimulated Akt and ERK1/2 responses were sensitive to PD98059 and LY294002 in VSMCs. As in HEK293-AT 1A cells, SII-stimulated Akt phosphorylation was unaffected by the MEK1 inhibitor, but abolished by PI3K inhibition (Fig. 6E) . Conversely, SII-stimulated ERK1/2 activation was sensitive to PD98059, but not LY294002. The attenuation of SII-stimulated ERK1/2 activation by LY294002 seen in HEK293-AT 1A cells (Fig. 3D) did not occur in VSMC, underscoring that arrestin-dependent regulation of ERK1/2 and Akt signaling are largely independent. AngII-stimulated Akt and ERK1/2 phosphorylation exhibited a similar pattern of inhibitor sensitivity.
As shown in Fig. 7A, 2 h stimulation of VSMCs with SII or AngII produced a significant increase in nascent protein abundance assayed by L-azidohomo-alanine incorporation. The response was blocked by cycloheximide, demonstrating that it was due to increased de novo protein translation. To test whether the response was arrestin-dependent in a native cell background, we employed lentiviral vectors to deliver shRNA targeting ␤arrestin1/2 (Fig. 7B) . Down-regulating ␤arrestin1/2 expression by 60 -70% led to an increase in basal protein translation compared with VSMC treated with control lentivirus. As in HEK293 FRT/TO ␤arrestin1/2 shRNA cells, neither AngII nor SII stimulated protein translation following ␤arrestin1/2 down-regulation. In contrast, epidermal growth factor, which acts via a classical receptor tyrosine kinase, provoked similar net increases in protein translation in VSMC treated with either control or ␤arrestin1/2 shRNA lentivirus. Since ␤arrestin expression has been shown to tonically inhibit Akt-GSK3␤ signaling in dopaminergic neurons (14 -16), the increase in basal protein translation seen upon ␤arrestin1/2 down-regulation phos-mTOR(S2448) GAPDH Not Sig. Not Sig. may reflect de-repression of basal Akt activity. At the same time, loss of ␤arrestin scaffolds appears to uncouple AT 1 , but not epidermal growth factor, receptors from the translational machinery.
To determine the contribution of G protein-independent signaling to endogenous AT 1 receptor-stimulated protein translation, we tested whether the SII response was sensitive to ERK1/2, Akt, and mTORC1 inhibition. Consistent with our findings in HEK293-AT 1A cells, exposing rat VSMCs to PD98059, the phosphatidylinositol 3-kinase inhibitor LY294002, rapamycin, or PP242 completely blocked SIIstimulated L-azidohomo-alanine incorporation (Fig. 7C) . The native agonist, AngII, also demonstrated co-dependence on ERK1/2, Akt, and mTORC1.
DISCUSSION
Regulation of the protein translational machinery by extracellular signals involves complex interplay between the ERK1/2-p90RSK and Akt-mTORC1-p70S6K pathways that regulate ribosomal eIFs, eEFs, and eRFs (Fig. 1A ). Our data demonstrate that arrestin-dependent signals regulating both ERK1/2 and Akt downstream of the angiotensin AT 1A receptor are critical mediators of GPCR-regulated protein translation.
The co-regulation of protein translation by arrestin-dependent signaling is best demonstrated using SII, since this arrestin pathway-selective AT 1A receptor agonist is devoid of significant G protein efficacy (18, 19, 23) . SII elicits a protein translation response that is comparable in magnitude to that produced by AngII, and completely blocked by shRNA-mediated downregulation of ␤arrestin1/2. As previously reported (12, 13) , activation of p90RSK by SII is ERK1/2 dependent, in that it is abolished by MEK1/2-ERK1/2 inhibition and not significantly affected by PDK1-Akt inhibition. In contrast, both ERK1/2 and Akt signaling are involved in activation of the mTORC1-p70/ 85S6K pathway. The two signals converge at the level of mTORC1, since inhibiting either is sufficient to impair mTORC1 Ser-2448 phosphorylation, p70/85S6K Thr-421/ FIGURE 6. SII independently stimulates ERK1/2 and Akt activation in primary rat aortic VSMCs. A, effect of AngII or SII on ERK1/2 and Akt phosphorylation. Serum-deprived VSMCs were stimulated for 5 min with AngII (100 nM) or SII (50 M) prior to performing phospho-Akt and phospho-ERK1/2 immunoblots on whole cell lysates. In each panel, representative immunoblots are shown above a bar graph depicting the Mean Ϯ S.E. of three biological replicates. B, down-regulating ␤arrestin1/2 expression attenuates SII-mediated Akt phosphorylation. Rat aortic VSMCs were infected with lentiviral vectors encoding shRNA targeting ␤arrestin1/2 or control lentivirus. After serum deprivation, cells were stimulated for 5 min with SII prior to performing phospho-Akt immunoblots on whole cell lysates. A representative phospho-Akt mmunoblot is shown above a bar graph depicting the Mean Ϯ S.E. of three biological replicates. GAPDH was immunoblotted as a protein loading control. A representative ␤arrestin immunoblot of control and ␤arrestin1/2 shRNA lentivirus treated VSMCs is shown to the right. C, time course of AngII-and SII-stimulated Akt and ERK1/2 phosphorylation. Serum-deprived rat aortic VSMCs were stimulated for the indicated times with AngII (100 nM) or SII (50 M) prior to performing phospho-Akt and phospho-ERK1/2 immunoblots on whole cell lysates. In each panel, representative immunoblots are shown above a bar graph depicting the mean Ϯ S.E. of three biological replicates. D, dose dependence of AngII-and SII-stimulated Akt and ERK1/2 phosphorylation. Serum-deprived rat aortic VSMCs were stimulated for 5 min with the indicated concentrations of AngII or SII prior to performing phospho-Akt and phospho-ERK1/2 immunoblots on whole cell lysates. In each panel, representative immunoblots are shown above a bar graph depicting the mean Ϯ S.E. of three biological replicates. EC 50 values were derived by curve fitting using GraphPad Prism software. E, effect of MEK and PI3K inhibitors on AngII and SII-stimulated Akt and ERK1/2 phosphorylation. Serum-deprived rat aortic VSMCs were pretreated with PD98059 (20 M; 1 h) or LY294002 (10 M; 1 h) prior to 5 min stimulation with AngII or SII. Levels of whole cell phospho-Akt and -ERK1/2 were determined by immunoblotting whole cell lysates. Representative immunoblots are shown above a bar graph depicting the mean Ϯ S.E. of three biological replicates. In all panels; * greater than non-stimulated (NS), p Ͻ 0.05, n ϭ 3; † less than in the absence of inhibitor, p Ͻ 0.05, n ϭ 3.
Ser-424 phosphorylation, and mTORC1-dependent protein translation.
As with SII, stimulation of protein translation by AngII is both arrestin-and mTORC1-dependent. In HEK293-AT 1A cells, AngII and SII produce comparable activation of arrestinbound Akt, while AngII, which can activate both hetero-trimeric G protein and arrestin signaling, produces more robust ERK1/2 activation. While this enhanced ERK1/2 activation may render AngII-stimulated p70/85S6K phosphorylation less sensitive to Akt and mTORC1 inhibition, AngII-induced protein translation in both HEK293-AT 1A cells and primary VSMCs requires Akt and mTORC1 activity, indicating that the Akt-mTORC1-p70/85S6K pathway is as important for the native ligand as for SII.
The non-visual arrestins, ␤arrestin1/2, perform dual roles in modulating GPCR signaling; serving both as the principal mediators of GPCR desensitization and internalization, and as signal transducers that confer additional G protein-independent signaling capability (31) . Many arrestin-dependent signals result from scaffolding protein kinase and/or phosphatase cascades within receptor-arrestin signalsomes (32) . Of these, scaffolding of cRaf1-MEK-ERK1/2 and PP2A-Akt-GSK3␤ complexes is among the best characterized. Arrestins recruit a cRaf1-MEK-ERK1/2 complex to agonist-occupied GPCRs, leading to sustained activation of a spatially, temporally and functionally discrete ERK1/2 pool (8 -11, 33) . Our present data support the hypothesis that one important function of this ERK1/2 pool is to regulate protein translation by activating the MAPKAPKs, p90RSK, and MNK-1, and serving as a co-activator of the mTORC1-p70/85S6K pathway.
A native ␤arrestin2-PP2A-Akt-GSK3␤ complex has been isolated from striatum (15) , where it is involved in the regulation of dopamine-dependent behavior (14 -16) . Arrestins have been implicated in Akt regulation by several GPCRs, including the angiotensin AT 1A (18) , ghrelin (34) , and ␣-thrombin (35) receptors. We have previously described a mechanism for rapid NS Cycloheximide SII AngII Not Sig. β arrestin1/2 FIGURE 7. SII stimulated protein synthesis in primary rat VSMCs requires ERK1/2, Akt, mTORC1, and ␤arrestin1/2. A, SII stimulates nascent protein synthesis in primary VSMCs. Serum-deprived rat VSMCs were pretreated with the translation inhibitor, cycloheximide (2 g/ml; 6 h), prior to stimulation with AngII or SII for 2 h, and protein synthesis was measured by L-azidohomoalanine pulse labeling. The bar graph depicts the mean Ϯ S.E. of three biological replicates. The micrographs depict representative fields of non-stimulated (NS), AngII-and SII-treated cells with and without cycloheximide exposure following Click-iTா AHA Alexa Fluorா 488 labeling (green). Hoechst 33342-labeled cell nuclei are blue. In both panels; * greater than nonstimulated (NS), p Ͻ 0.05, n ϭ 3. B, nascent protein synthesis in VSMCs after down-regulation of ␤arrestin1/2 using lentiviral vectors. The top panel depicts a representative ␤arrestin1/2 immunoblot of VSMCs following treatment with either ␤arrestin1/2-targeted or control lentivirus. The bar graph depicts the mean Ϯ S.E. of three biological replicates. C, effect of ERK1/2, Akt and mTORC1 inhibitors on SII-stimulated protein synthesis. Serum-deprived rat VSMCs were pretreated with PD98059 (20 M; 1 h), LY294002 (10 M; 1 h), rapamycin (2 nM; 30 min), or PP242 (100 nM; 30 min), prior to stimulation 2 h with AngII or SII, and protein synthesis was measured by L-azidohomoalanine pulse labeling. The bar graph depicts the mean Ϯ S.E. of three biological replicates. In all panels; * greater than nonstimulated (NS), p Ͻ 0.05, n ϭ 3.
AT 1A receptor-mediated activation of arrestin-bound Akt resulting from SII-or AngII-stimulated phosphorylation of I2PP2A, inhibition of PP2A, and relief of tonic PP2A-mediated inhibition of Akt in the signalsome complex (18) . Our present data suggest that an important function of this arrestin-bound Akt pool is to activate the mTORC1-p70/85S6K pathway, which in conjunction with ERK1/2, leads to increased mTORC1-dependent protein translation.
Arrestin-dependent signaling has been shown to exert pleiotropic effects in cardiovascular tissues (36) . Arrestin pathwayselective AT 1 receptor agonists have been reported to improve contractile parameters in isolated murine cardiomyocytes (37) , to reduce blood pressure and improve cardiac performance in vivo (38) , and to promote cardiomyocyte survival during acute cardiac injury (39) . Indeed, an arrestin-biased angiotensin analog, TRV120023 (Sar-Arg-Val-Tyr-Lys-His-Pro-Ala-OH), that possesses higher affinity for the AT 1 receptor than SII, has been advanced as a potential therapeutic in cardiogenic shock (38 -40) . On the other hand, ␤arrestin2-null mice exhibit reduced neointimal VSMC hyperplasia following endothelial injury, and SII stimulates VSMC proliferation, migration, and anti-apoptotic signaling in vitro (17, 41, 42) , suggesting that arrestin-dependent AT 1 receptor signaling may promote atherosclerosis. Moreover, in the adrenal, ␤arrestin1 signaling underlies AngIIinduced aldosterone biosynthesis, and inhibition of adrenal ␤arrestin1 signaling in vivo attenuates post-myocardial infarction heart failure and adverse remodeling by inhibiting aldosterone-dependent salt retention (43, 44) . Our present data demonstrating a central role for arrestin-dependent ERK1/2 and Akt signaling in AT 1 receptor regulation of the mTOCR1 complex further suggests that arrestin-dependent signaling may promote adverse effects in the cardiovascular system by stimulating cellular growth, hyperplasia, and proliferation.
